The utility of BNP in clinical pratice

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 5, Issue 2, 2004, Pages 53-58

  Sharp, Andrew ^a   Mayet, Jamil ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

BNP; Heart failure; Natriuretic; Nesiritide; Peptide

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; MOLECULAR MARKER; NESIRITIDE; NEUROHORMONE; NITRIC ACID DERIVATIVE; SYNTHETIC PEPTIDE;

CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DIASTOLE; DRUG EFFICACY; DYSPNEA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HORMONE RELEASE; HORMONE STRUCTURE; HUMAN; HYPOTENSION; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SCREENING;

EID: 3542992669     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2004.010     Document Type: Review

References (43)

1. Mukoyama M, Nakao K, Hosoda K et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87: 1402-12.
2. Hosoda K, Nakao K, Mukoyama M et al. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension 1991;17:1152-6.
3. Nakao K, Mukoyama M, Hosoda K et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991;69:1500-06.
4. Nakagawa O, Ogawa Y, Itoh H et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-7.
5. Yeo KT, Wu AH, Apple FS et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107-15.
6. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004;341:41-8.
7. McLean AS, Huang SJ, Nalos M,Tang B, Stewart DE. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med 2003;31: 2611-18.
8. McCullough PA, Duc P, Omland T et al., Breathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-9.
9. Maisel AS, McCord J, Nowak RM et al., Breathing Not Properly Multinational Study Investigators. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003;41:2010-17.
10. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003;42:728-35.
11. Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
12. Lee SC, Stevens TL, Sandberg SM et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002;8:149-54.
13. Harrison A, Morrison LK, Krishnaswamy P et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8.
14. Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53.
15. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105:1387-93.
16. Appleton CP, Firstenberg MS, Garcia MJ, Thomas JD. The echo-Doppler evaluation of left ventricular diastolic function. A current perspective. Cardiol Clin 2000;18:513-46, ix.
17. Lubien E, DeMaria A, Krishnaswamy P et al. Utility of B-natriuretic peptide (BNP) in diagnosing diastolic dysfunction. Circulation 2002;105:595-601.
18. Ambrosi P, Oddoze C, Habib G. Comment on: Circulation 2002;105:595-601. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;106:e70.
19. Yamaguchi H, Yoshida J, Yamamoto K et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004;43:55-60.
20. Almeida P, Azevedo A, Rodrigues R et al. B-type natriuretic peptide and left ventricular hypertrophy in hypertensive patients. Rev Port Cardiol 2003;22:327-36. English, Portuguese
21. Vasan RS, Benjamin EJ, Larson MG et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002;288:1252-9.
22. Nakamura M, Tanaka F, Yonezawa S, Satou K, Nagano M, Hiramori K. The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens 2003;16:1025-9.
23. Wang TJ, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
24. Sabatine MS, Morrow DA, de Lemos JA et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-3.
25. Morrow DA, de Lemos JA, Sabatine MS et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-72. Erratum in: J Am Coll Cardiol 2003;41:1852.
26. Omland T, Persson A, Ng L, O'Brien R et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acure coronary syndromes. Circulation 2002;106:2913-18.
27. Inoue T, Sakuma M,Yaguchi I et al. Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. Am Heart J 2002;143:790-6.
28. Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998;135:914-23.
29. Arakawa N, Nakamura M,Aoki H, Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996;27:1656-61.
30. Horio T, Shimada K, Kohno M et al. Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty. Am Heart J 1993;126:293-9.
31. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 2000;23:776-80.
32. Kyriakides ZS, Markianos M, Michalis L, Antoniadis A, Nikolaou NI, Kremastinos DT. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin Cardiol 2000;23: 285-8.
33. Klinge R, Jorgensen B,Thaulow E, Sirnes PA, Hall C. N-terminal proatrial natriuretic peptide in angina pectoris: impact of revascularization by angioplasty. Int J Cardiol 1999;68:18.
34. Watanabe M, Egi K, Hasegawa S et al. Significance of serum atrial and brain natriuretic peptide release after coronary artery bypass grafting. Surg Today 2003;33:671-3.
35. Goetze JP, Christoffersen C, Perko M et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003;17:1105-07. Epub 2003 Apr 22.
36. Kruger S, Graf J, Merx MW et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004;147:60-5.
37. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003;45:249-54.
38. Leuchte HH, Neurohr C, Baumgartner R et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 15:epub ahead of print.
39. Troughton RW, Prior DL, Pereira JJ et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importante of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 2004;43:416-22.
40. Leuchte HH, Holzapfel M, Baumgartner RA et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-70.
41. Mariano-Goulart D, Eberle MC, Boudousq V et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail 2003;5:481-8.
42. Burger AJ, Horton DP, LeJemtel T et al. Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144: 1102-08.
43. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.